LinusBio

LinusBio, a pioneering platform company, is developing precision exposome biomarkers to enable earlier diagnoses, enhance patient monitoring, and accelerate drug development.
Originating from the world’s leading exposome laboratory at Mount Sinai Health System, LinusBio has developed a technology platform that builds on breakthroughs in exposome sequencing by researcher, founder, and CEO Dr. Manish Arora.
The Company’s program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease, oncology and more.